 |
PDBsum entry 2ahx
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Cell cycle,signaling protein
|
PDB id
|
|
|
|
2ahx
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.2.7.10.1
- receptor protein-tyrosine kinase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + ADP + H+
|
 |
 |
 |
 |
 |
L-tyrosyl-[protein]
|
+
|
ATP
Bound ligand (Het Group name = )
matches with 47.62% similarity
|
=
|
O-phospho-L-tyrosyl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Proc Natl Acad Sci U S A
102:15024-15029
(2005)
|
|
PubMed id:
|
|
|
|
|
| |
|
The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand.
|
|
S.Bouyain,
P.A.Longo,
S.Li,
K.M.Ferguson,
D.J.Leahy.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The human ErbB family of receptor tyrosine kinases comprises the epidermal
growth factor receptor (EGFR/ErbB1/HER1), ErbB2 (HER2/Neu), ErbB3 (HER3), and
ErbB4 (HER4). ErbBs play fundamental roles in cell growth and differentiation
events in embryonic and adult tissues, and inappropriate ErbB activity has been
implicated in several human cancers. We report here the 2.4 A crystal structure
of the extracellular region of human ErbB4 in the absence of ligand and show
that it adopts a tethered conformation similar to inactive forms of ErbB1 and
ErbB3. This structure completes the gallery of unliganded ErbB receptors and
demonstrates that all human ligand-binding ErbBs adopt the autoinhibited
conformation. We also show that the binding of neuregulin-1beta to ErbB4 and
ErbB3 and the binding of betacellulin to both ErbB4 and ErbB1 does not decrease
at low pH, unlike the binding of epidermal growth factor and transforming growth
factor-alpha to ErbB1. These results indicate an important role for ligand in
determining pH-dependent binding and may explain different responses observed
when the same ErbB receptor is stimulated by different ligands.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 2.
Fig. 2. Structure of sErbB4. (A) Ribbon diagram of sErbB4.
Domains I, II, III, and IV are colored blue, green, yellow, and
red, respectively. The N and C termini are indicated by the
letters N and C. (B) Surface representation of sErbB4. The
intramolecular contact between domains II and IV is boxed. (C)
Domain II/IV contact in ligand-binding sErbBs. Residues at the
tether between domains II and IV of sErbB4 are shown in green
(domain II) and red (domain IV). The equivalent residues from
tethered sErbB1 and sErbB3 are shown in gray and white,
respectively (3, 6). The buried surface areas and the surface
complementarity coefficients for each tether are indicated in
the legend.
|
 |
Figure 3.
Fig. 3. Comparison of ligand-binding surfaces in sErbB1 and
sErbB4. (A) Conservation of sErbB1 TGF- -binding residues in
sErbB4. Residues with atoms within4Åofa TGF- residue
are shown in red on surface representations of sErbB1 domains I
and III (4). Residues that are strictly conserved between the
ErbB1 ligand-binding site and ErbB4 are colored blue on surface
representations of sErbB4. (B) Electrostatic potential on the
ligand-binding surfaces of ErbB1 and ErbB4. Regions with
negative electrostatic potential are colored red and regions
with positive electrostatic potential are colored blue (scale
± 10 e/kT).
|
 |
|
|
| |
Figures were
selected
by the author.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
Y.Yarden,
and
G.Pines
(2012).
The ERBB network: at last, cancer therapy meets systems biology.
|
| |
Nat Rev Cancer,
12,
553-563.
|
 |
|
|
|
|
 |
D.Alvarado,
D.E.Klein,
and
M.A.Lemmon
(2010).
Structural basis for negative cooperativity in growth factor binding to an EGF receptor.
|
| |
Cell,
142,
568-579.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
F.Cymer,
and
D.Schneider
(2010).
Transmembrane helix-helix interactions involved in ErbB receptor signaling.
|
| |
Cell Adh Migr,
4,
299-312.
|
 |
|
|
|
|
 |
F.Zhang,
S.Weggler,
M.J.Ziller,
L.Ianeselli,
B.S.Heck,
A.Hildebrandt,
O.Kohlbacher,
M.W.Skoda,
R.M.Jacobs,
and
F.Schreiber
(2010).
Universality of protein reentrant condensation in solution induced by multivalent metal ions.
|
| |
Proteins,
78,
3450-3457.
|
 |
|
|
|
|
 |
L.Chen,
J.Placone,
L.Novicky,
and
K.Hristova
(2010).
The extracellular domain of fibroblast growth factor receptor 3 inhibits ligand-independent dimerization.
|
| |
Sci Signal,
3,
ra86.
|
 |
|
|
|
|
 |
T.Otani,
T.Hashizume,
T.Nagaoka,
T.Fukuda,
C.K.Tang,
D.S.Salomon,
and
M.Seno
(2010).
Production of biologically active IgG hinge-tag soluble epidermal growth factor receptors (ErbB).
|
| |
Biotechnol Lett,
32,
361-366.
|
 |
|
|
|
|
 |
C.Qiu,
M.K.Tarrant,
T.Boronina,
P.A.Longo,
J.M.Kavran,
R.N.Cole,
P.A.Cole,
and
D.J.Leahy
(2009).
In vitro enzymatic characterization of near full length EGFR in activated and inhibited states.
|
| |
Biochemistry,
48,
6624-6632.
|
 |
|
|
|
|
 |
D.Alvarado,
D.E.Klein,
and
M.A.Lemmon
(2009).
ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor.
|
| |
Nature,
461,
287-291.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
K.L.Carraway,
and
G.A.Kozloski
(2009).
Conformational changes in receptor tyrosine kinase signaling: an ErbB garden of delights.
|
| |
F1000 Biol Rep,
1,
1-4.
|
 |
|
|
|
|
 |
K.R.Schmitz,
and
K.M.Ferguson
(2009).
Interaction of antibodies with ErbB receptor extracellular regions.
|
| |
Exp Cell Res,
315,
659-670.
|
 |
|
|
|
|
 |
L.Chen,
M.Merzlyakov,
T.Cohen,
Y.Shai,
and
K.Hristova
(2009).
Energetics of ErbB1 transmembrane domain dimerization in lipid bilayers.
|
| |
Biophys J,
96,
4622-4630.
|
 |
|
|
|
|
 |
P.Jin,
J.Zhang,
M.Beryt,
L.Turin,
C.Brdlik,
Y.Feng,
X.Bai,
J.Liu,
B.Jorgensen,
and
H.M.Shepard
(2009).
Rational optimization of a bispecific ligand trap targeting EGF receptor family ligands.
|
| |
Mol Med,
15,
11-20.
|
 |
|
|
|
|
 |
S.E.Telesco,
and
R.Radhakrishnan
(2009).
Atomistic insights into regulatory mechanisms of the HER2 tyrosine kinase domain: a molecular dynamics study.
|
| |
Biophys J,
96,
2321-2334.
|
 |
|
|
|
|
 |
S.O'Connor,
E.Li,
B.S.Majors,
L.He,
J.Placone,
D.Baycin,
M.J.Betenbaugh,
and
K.Hristova
(2009).
Increased expression of the integral membrane protein ErbB2 in Chinese hamster ovary cells expressing the anti-apoptotic gene Bcl-xL.
|
| |
Protein Expr Purif,
67,
41-47.
|
 |
|
|
|
|
 |
T.D.Prickett,
N.S.Agrawal,
X.Wei,
K.E.Yates,
J.C.Lin,
J.R.Wunderlich,
J.C.Cronin,
P.Cruz,
S.A.Rosenberg,
and
Y.Samuels
(2009).
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.
|
| |
Nat Genet,
41,
1127-1132.
|
 |
|
|
|
|
 |
C.Qiu,
M.K.Tarrant,
S.H.Choi,
A.Sathyamurthy,
R.Bose,
S.Banjade,
A.Pal,
W.G.Bornmann,
M.A.Lemmon,
P.A.Cole,
and
D.J.Leahy
(2008).
Mechanism of activation and inhibition of the HER4/ErbB4 kinase.
|
| |
Structure,
16,
460-467.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
G.Sithanandam,
and
L.M.Anderson
(2008).
The ERBB3 receptor in cancer and cancer gene therapy.
|
| |
Cancer Gene Ther,
15,
413-448.
|
 |
|
|
|
|
 |
J.Schmiedel,
A.Blaukat,
S.Li,
T.Knöchel,
and
K.M.Ferguson
(2008).
Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization.
|
| |
Cancer Cell,
13,
365-373.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
K.M.Ferguson
(2008).
Structure-based view of epidermal growth factor receptor regulation.
|
| |
Annu Rev Biophys,
37,
353-373.
|
 |
|
|
|
|
 |
K.Roepstorff,
L.Grøvdal,
M.Grandal,
M.Lerdrup,
and
B.van Deurs
(2008).
Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer.
|
| |
Histochem Cell Biol,
129,
563-578.
|
 |
|
|
|
|
 |
M.J.Wieduwilt,
and
M.M.Moasser
(2008).
The epidermal growth factor receptor family: biology driving targeted therapeutics.
|
| |
Cell Mol Life Sci,
65,
1566-1584.
|
 |
|
|
|
|
 |
M.Landau,
and
N.Ben-Tal
(2008).
Dynamic equilibrium between multiple active and inactive conformations explains regulation and oncogenic mutations in ErbB receptors.
|
| |
Biochim Biophys Acta,
1785,
12-31.
|
 |
|
|
|
|
 |
O.Samna Soumana,
N.Garnier,
and
M.Genest
(2008).
Insight into the recognition patterns of the ErbB receptor family transmembrane domains: heterodimerization models through molecular dynamics search.
|
| |
Eur Biophys J,
37,
851-864.
|
 |
|
|
|
|
 |
S.Li,
P.Kussie,
and
K.M.Ferguson
(2008).
Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8.
|
| |
Structure,
16,
216-227.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
C.W.Ward,
M.C.Lawrence,
V.A.Streltsov,
T.E.Adams,
and
N.M.McKern
(2007).
The insulin and EGF receptor structures: new insights into ligand-induced receptor activation.
|
| |
Trends Biochem Sci,
32,
129-137.
|
 |
|
|
|
|
 |
D.J.Riese,
R.M.Gallo,
and
J.Settleman
(2007).
Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis.
|
| |
Bioessays,
29,
558-565.
|
 |
|
|
|
|
 |
E.M.Bublil,
and
Y.Yarden
(2007).
The EGF receptor family: spearheading a merger of signaling and therapeutics.
|
| |
Curr Opin Cell Biol,
19,
124-134.
|
 |
|
|
|
|
 |
H.Zhang,
A.Berezov,
Q.Wang,
G.Zhang,
J.Drebin,
R.Murali,
and
M.I.Greene
(2007).
ErbB receptors: from oncogenes to targeted cancer therapies.
|
| |
J Clin Invest,
117,
2051-2058.
|
 |
|
|
|
|
 |
J.P.Dawson,
Z.Bu,
and
M.A.Lemmon
(2007).
Ligand-induced structural transitions in ErbB receptor extracellular domains.
|
| |
Structure,
15,
942-954.
|
 |
|
|
|
|
 |
R.Landgraf
(2007).
HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks.
|
| |
Breast Cancer Res,
9,
202.
|
 |
|
|
|
|
 |
S.L.Chen,
S.T.Lin,
T.C.Tsai,
W.C.Hsiao,
and
Y.P.Tsao
(2007).
ErbB4 (JM-b/CYT-1)-induced expression and phosphorylation of c-Jun is abrogated by human papillomavirus type 16 E5 protein.
|
| |
Oncogene,
26,
42-53.
|
 |
|
|
|
|
 |
W.Xu,
X.Yuan,
K.Beebe,
Z.Xiang,
and
L.Neckers
(2007).
Loss of Hsp90 association up-regulates Src-dependent ErbB2 activity.
|
| |
Mol Cell Biol,
27,
220-228.
|
 |
|
|
|
|
 |
A.Yasmeen,
T.A.Bismar,
and
A.E.Al Moustafa
(2006).
ErbB receptors and epithelial-cadherin-catenin complex in human carcinomas.
|
| |
Future Oncol,
2,
765-781.
|
 |
|
|
|
|
 |
C.Sweeney,
J.K.Miller,
D.L.Shattuck,
and
K.L.Carraway
(2006).
ErbB receptor negative regulatory mechanisms: implications in cancer.
|
| |
J Mammary Gland Biol Neoplasia,
11,
89-99.
|
 |
|
|
|
|
 |
R.A.Stein,
and
J.V.Staros
(2006).
Insights into the evolution of the ErbB receptor family and their ligands from sequence analysis.
|
| |
BMC Evol Biol,
6,
79.
|
 |
|
|
|
|
 |
R.L.Rich,
and
D.G.Myszka
(2006).
Survey of the year 2005 commercial optical biosensor literature.
|
| |
J Mol Recognit,
19,
478-534.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |